Kathryn Collier Biography and Net Worth



Kathryn J. Collier has served on our board of directors since April 2018. From March 2022 until February 2024, Ms. Collier served as the senior vice president of corporate finance for Pattern Energy Group LP, a privately held renewable energy company. From July 2019 to March 2022, Ms. Collier served as the vice president for audit services of Sempra Energy (“Sempra”), a publicly traded energy services holding company overseeing the internal audit function for Sempra, including the Financial Leadership Program and audit oversight of Sempra’s operating companies. From March 2019 to July 2019, Ms. Collier served as the chief strategy and origination officer for Sempra LNG, a wholly-owned subsidiary of Sempra. From August 2018 to March 2019, Ms. Collier served as chief financial officer and chief administrative officer for Sempra North America Infrastructure. Ms. Collier also previously served as vice president and treasurer for Sempra from April 2012 to August 2018. Prior to joining Sempra in 2012, Ms. Collier held several executive positions within global corporate and investment banking at Bank of America Merrill Lynch. Ms. Collier holds a B.A. in accounting from Valparaiso University.

What is Kathryn J. Collier's net worth?

The estimated net worth of Kathryn J. Collier is at least $55.00 thousand as of July 25th, 2024. Ms. Collier owns 6,740 shares of Regulus Therapeutics stock worth more than $54,998 as of December 5th. This net worth evaluation does not reflect any other investments that Ms. Collier may own. Learn More about Kathryn J. Collier's net worth.

How do I contact Kathryn J. Collier?

The corporate mailing address for Ms. Collier and other Regulus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Regulus Therapeutics can also be reached via phone at (858) 202-6300 and via email at [email protected]. Learn More on Kathryn J. Collier's contact information.

Has Kathryn J. Collier been buying or selling shares of Regulus Therapeutics?

Kathryn J. Collier has not been actively trading shares of Regulus Therapeutics during the last ninety days. Most recently, on Thursday, July 25th, Kathryn J. Collier bought 4,000 shares of Regulus Therapeutics stock. The stock was acquired at an average cost of $1.82 per share, with a total value of $7,280.00. Following the completion of the transaction, the director now directly owns 6,740 shares of the company's stock, valued at $12,266.80. Learn More on Kathryn J. Collier's trading history.

Who are Regulus Therapeutics' active insiders?

Regulus Therapeutics' insider roster includes Christopher Aker (VP), David Baltimore (Director), Crispina Calsada (CFO), Kathryn Collier (Director), Denis Drygin (Insider), Joseph Hagan (CEO), and Preston Klassen (Insider). Learn More on Regulus Therapeutics' active insiders.

Are insiders buying or selling shares of Regulus Therapeutics?

During the last twelve months, Regulus Therapeutics insiders bought shares 3 times. They purchased a total of 81,610 shares worth more than $171,166.60. During the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 223,998 shares worth more than $282,237.48. The most recent insider tranaction occured on June, 3rd when insider Preston Klassen bought 12,000 shares worth more than $95,880.00. Insiders at Regulus Therapeutics own 4.4% of the company. Learn More about insider trades at Regulus Therapeutics.

Information on this page was last updated on 6/3/2025.

Kathryn J. Collier Insider Trading History at Regulus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/25/2024Buy4,000$1.82$7,280.006,740View SEC Filing Icon  
11/16/2018Buy7,100$1.41$10,011.0027,596View SEC Filing Icon  
See Full Table

Kathryn J. Collier Buying and Selling Activity at Regulus Therapeutics

This chart shows Kathryn J Collier's buying and selling at Regulus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regulus Therapeutics Company Overview

Regulus Therapeutics logo
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $8.16
Low: $8.16
High: $8.16

50 Day Range

MA: $8.10
Low: $7.87
High: $8.30

2 Week Range

Now: $8.16
Low: $0.83
High: $8.35

Volume

N/A

Average Volume

1,018,158 shs

Market Capitalization

$564.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35